Funded Startups in Malvern
Across the 14 most recent Malvern rounds shown, one disclosed outlier stands out: Ocugen’s $115M (2026-05-04).
Across the 14 most recent Malvern rounds shown, one disclosed outlier stands out: Ocugen’s $115M (2026-05-04). The next-largest disclosed amounts—Aclaris Therapeutics at $80M (2024-11-18) and Neuronetics at $60M (2023-04-04)—sit well below Ocugen, while several others cluster closer to the $2M–$46M range (for example Baudax Bio at $2M on 2023-08-17 and Ovum at $3M on 2026-06-22). The list also concentrates geographically: 13 of 14 entries are in Malvern, Pennsylvania (United States), with one in Malvern, Victoria (Australia) (Ovum, 2026-06-22). Timing is similarly tight in the most recent window: 4 of 14 rounds fall between 2026-05-04 and 2026-06-22. Sector-wise, biotech dominates, with Biotechnology appearing in 8 of 14 entries, and “Series Unknown” appears in 6 of 14 rows; one row is explicitly “undisclosed” (AKUVO, 2025-09-21).
Most recent rounds
14 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Malvern slice, and how far above the rest is it?
Ocugen’s $115M on 2026-05-04 is the only disclosed round above $100M. The next-largest disclosed amounts are $80M (Aclaris Therapeutics, 2024-11-18) and $60M (Neuronetics, 2023-04-04), both materially lower than Ocugen.
Do these Malvern deals cluster in a specific time window?
Yes. Four of the 14 rounds close between 2026-05-04 (Ocugen) and 2026-06-22 (Ovum): Ocugen ($115M), 20n Bio ($8M, 2026-05-20), Pretura Health ($50K, 2026-06-09), and Ovum ($3M, 2026-06-22). The overall span runs from 2022-04-11 (Momentum Dynamics) to 2026-06-22 (Ovum).
Is Malvern, Pennsylvania more common than other Malvern locations in this list?
Predominantly. 13 of 14 entries list Malvern, Pennsylvania, United States; the only exception is Ovum in Malvern, Victoria, Australia (Seed, 2026-06-22, $3M).
Which sectors are over-represented compared with everything else here?
Biotechnology is the clear concentration: 8 of 14 entries are tagged Biotechnology (e.g., Ocugen $115M on 2026-05-04; Neuronetics $60M on 2023-04-04; Aclaris Therapeutics $80M on 2024-11-18). Financial Services appears 2 times (AKUVO, 2025-09-21; Savana, 2022-07-22), while Apps (Ovum), Apps/Consumer Electronics (Momentum Dynamics, 2022-04-11), and Health Care (Toetal Solutions, 2022-10-20) are singletons in this view.
How concentrated are stage labels like “Series Unknown” or “undisclosed” among the most recent rounds?
Stage information is frequently non-specific: 6 of 14 rows are labeled “Series Unknown” (for example Ocugen on 2026-05-04 and TELA Bio on 2024-10-23). One additional row is “undisclosed” (AKUVO on 2025-09-21), leaving only a smaller share with explicit stage labels like Seed, Pre-Seed, or Debt Financing.
Are there unusually small disclosed rounds that stand out against the rest?
Pretura Health’s $50K on 2026-06-09 is the smallest disclosed amount in the dataset. Other relatively small disclosed rounds include Ovum at $3M (2026-06-22) and Baudax Bio at $2M (2023-08-17), but neither is as low as Pretura Health compared with the broader $8M–$115M concentration.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.